Castration-Resistant Prostate Cancer Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

The report on the global castration-resistant prostate cancer treatment market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global castration-resistant prostate cancer treatment market to grow at a CAGR of 8% around the forecast period from 2021-2027. The study on castration-resistant prostate cancer treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, RoW, North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on castration-resistant prostate cancer treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global castration-resistant prostate cancer treatment market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global castration-resistant prostate cancer treatment market over the period of 2019 to 2027. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• The increasing number of clinical trials for the treatment of castrate-resistant prostate cancer is expected to boost the global castrate-resistant prostate cancer market over the forecasting years

2) Restraints

• Lack of awareness amongst the people about the treatments and lack of proper healthcare facilities present in a few developing countries will restrain the market growth

3) Opportunities

• The growing awareness regarding the treatment in highly developed countries and the surging geriatric population have created lucrative growth opportunities for the players to grow.

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global castration-resistant prostate cancer treatment market is segmented on the basis of therapy type, drug delivery method, and distribution channel.

The Global Castration-resistant Prostate Cancer Treatment Market by Therapy Type

• Chemotherapy
• Hormonal Therapy
• Immunotherapy
• Radiotherapy
• Chemotherapy

The Global Castration-resistant Prostate Cancer Treatment Market by Drug Delivery Method

• Oral Therapy
• Injectable Therapy
• Oral Therapy

The Global Castration-resistant Prostate Cancer Treatment Market by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Company Profiles

The companies covered in the report include

• Pfizer Inc.
• Astellas Inc
• Johnson & Johnson
• Sanofi S.A
• Dendreon Corporation
• Bayer AG
• GlaxoSmithKline PLC
• Northwest Biotherapeutics, Inc
• Active Biotech AB
• Dendreon Pharmaceuticals LLC
• Pfizer Inc.

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the castration-resistant prostate cancer treatment market.
2. Complete coverage of all the segments in the castration-resistant prostate cancer treatment market to analyze the trends, developments in the global market and forecast of market size up to 2027.
3. Comprehensive analysis of the companies operating in the global castration-resistant prostate cancer treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.